| Code | CSB-RA017647MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of SAL003, targeting PCSK9 (proprotein convertase subtilisin/kexin type 9)—a secreted regulator of cholesterol homeostasis that binds the LDL receptor (LDLR) on hepatocytes and promotes LDLR lysosomal degradation, reducing receptor recycling and lowering hepatic clearance of LDL-cholesterol. By driving LDLR turnover, PCSK9 activity contributes to elevated circulating LDL-C, making the PCSK9–LDLR axis a central pathway for studying dyslipidemia mechanisms and lipid-lowering intervention biology.
SAL003 is a recombinant fully human anti-PCSK9 monoclonal antibody (reported as originally derived from an IgG4 framework) developed for lipid-lowering indications such as hypercholesterolemia and mixed dyslipidemia. This biosimilar provides the antibody component alone, enabling researchers to investigate PCSK9 neutralization and its downstream consequences—such as LDLR preservation/recycling, LDL uptake dynamics in hepatocyte models, and pathway-level biomarker readouts—independent of statin background or other therapeutic variables. It supports assay development and benchmarking workflows for PCSK9-targeted discovery, including binding/neutralization characterization and functional LDLR/LDL-C surrogate readouts in controlled experimental systems.
There are currently no reviews for this product.